P
Paul S. Jones
Researcher at Cancer Research UK
Publications - 10
Citations - 437
Paul S. Jones is an academic researcher from Cancer Research UK. The author has contributed to research in topics: Cancer & Immunoglobulin E. The author has an hindex of 7, co-authored 10 publications receiving 308 citations.
Papers
More filters
Journal ArticleDOI
A framework for the development of effective anti-metastatic agents.
Robin L. Anderson,Robin L. Anderson,Theo Balasas,Juliana Callaghan,R. Charles Coombes,Jeff Evans,Jacqueline A. Hall,Sally A. Kinrade,David Jones,Paul S. Jones,Robert Jones,John Marshall,Maria Beatrice Panico,Jacqui Shaw,Patricia S. Steeg,Mark T. Sullivan,Warwick Tong,Andrew D. Westwell,James W. A. Ritchie +18 more
TL;DR: The challenges associated with discovering and developing anticancer agents designed specifically to prevent or delay the metastatic outgrowth of cancer are described and guidance on how these challenges might be overcome is provided.
Journal ArticleDOI
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Timothy A. Yap,Michael I. Walton,Kyla Grimshaw,Robert te Poele,Paul D. Eve,Melanie Valenti,Alexis De Haven Brandon,Vanessa Martins,Anna Zetterlund,Simon P. Heaton,Kathrin Heinzmann,Paul S. Jones,Ruth Feltell,Matthias Reule,Steven John Woodhead,T.G. Davies,John Lyons,Florence I. Raynaud,Suzanne A. Eccles,Paul Workman,Neil T. Thompson,Michelle D. Garrett +21 more
TL;DR: Gene expression studies showed that AT13148 has a predominant effect on apoptosis genes, whereas the selective AKT inhibitor CCT128930 modulates cell-cycle genes, which shows a distinct mechanism of action from other AKT inhibitors.
Journal ArticleDOI
Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.
Debra H. Josephs,Heather J. Bax,Tihomir Dodev,Tihomir Dodev,Mirella Georgouli,Mano Nakamura,Giulia Pellizzari,Louise Saul,Panagiotis Karagiannis,Anthony Cheung,Cecilia Herraiz,Kristina M. Ilieva,Isabel Correa,Matthew Fittall,Silvia Crescioli,Patrycja Gazinska,Natalie Woodman,Silvia Mele,Giulia Chiaruttini,Amy E. Gilbert,Alexander Koers,Marguerite G. Bracher,Christopher Selkirk,Heike Lentfer,Claire Barton,Elliott Lever,Gareth Muirhead,Sophia Tsoka,Silvana Canevari,Mariangela Figini,Ana Montes,Noel Downes,David Dombrowicz,Christopher Corrigan,Andrew J. Beavil,Andrew J. Beavil,Frank O. Nestle,Paul S. Jones,Hannah J. Gould,Hannah J. Gould,Victoria Sanz-Moreno,Philip J. Blower,James Spicer,Sophia N. Karagiannis +43 more
TL;DR: Findings show how antitumor IgE reprograms monocytes and macrophages in the tumor microenvironment, encouraging the clinical use of IgE antibody technology to attack cancer beyond the present exclusive reliance on IgG.
Journal ArticleDOI
Beta-glucan contamination of pharmaceutical products: How much should we accept?
Claire Barton,Kim Vigor,Robert Scott,Paul S. Jones,Heike Lentfer,Heather J. Bax,Debra H. Josephs,Sophia N. Karagiannis,James Spicer +8 more
TL;DR: An acceptable level for therapeutic agents for parenteral use is proposed for beta-glucan levels in pharmaceutical products, especially those with an immunomodulatory mechanism of action.
Journal ArticleDOI
Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome.
Heather J. Bax,Jitesh Chauhan,Chara Stavraka,Chara Stavraka,Atousa Khiabany,Mano Nakamura,Giulia Pellizzari,Kristina M. Ilieva,Sara A. Lombardi,Hannah J. Gould,Christopher Corrigan,Stephen J. Till,Sidath Katugampola,Paul S. Jones,Claire Barton,Anna Winship,Sharmistha Ghosh,Ana Montes,Debra H. Josephs,Debra H. Josephs,James Spicer,Sophia N. Karagiannis +21 more
TL;DR: Greater numbers of circulating basophils, cells with greater capacity for ex vivo stimulation, and gene signatures indicating the presence of activated basophil in tumors were each associated with improved survival in ovarian cancer.